Alnylam Pharmaceuticals (ALNY) Common Equity (2009 - 2026)

Alnylam Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• Quarterly Common Equity rose 152.35% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 152.35% YoY) and the FY2025 annual result came in at $789.2 million, up 1076.33% from the prior year.
• Common Equity was $1.1 billion for Q1 2026 at Alnylam Pharmaceuticals, up from $789.2 million in the prior quarter.
• Across five years, Common Equity topped out at $1.1 billion in Q1 2026 and bottomed at -$408.1 million in Q2 2023.
• A 5-year average of $114.7 million and a median of $32.4 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity tumbled 331.84% — and 2025, when it surged 8270.56%.
• Alnylam Pharmaceuticals' Common Equity stood at -$158.2 million in 2022, then plunged by 39.45% to -$220.6 million in 2023, then jumped by 130.41% to $67.1 million in 2024, then soared by 1076.33% to $789.2 million in 2025, then soared by 36.27% to $1.1 billion in 2026.
• Business Quant data shows ALNY's Common Equity at $1.1 billion in Q1 2026, $789.2 million in Q4 2025, and $233.9 million in Q3 2025.